Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.

Circulating tumor DNA Head and neck cancer Human papillomavirus Oropharyngeal cancer Tumor-tissue modified viral HPV DNA

Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
14 Jun 2024
Historique:
received: 01 03 2024
revised: 27 05 2024
accepted: 27 05 2024
medline: 16 6 2024
pubmed: 16 6 2024
entrez: 15 6 2024
Statut: aheadofprint

Résumé

Clinical and imaging examinations frequently have indeterminate results during cancer surveillance, which can lead to overtreatment and cause psychological and financial harm to the patient. This study addresses the critical need to enhance diagnostic precision and decision-making in the management of HPV-associated oropharyngeal cancer. This study evaluated the utility of tumor tissue-modified viral (TTMV)-HPV DNA to resolve indeterminate disease status following definitive treatment for HPV-associated oropharyngeal cancer. In this retrospective cohort, patients treated for HPV-associated oropharyngeal cancer at eight U.S. institutions and who received one or more TTMV-HPV DNA tests during post-treatment surveillance between February 2020 and January 2022 were included. Among 543 patients, 210 patients (38.7%; 210/543) experienced one or more clinically indeterminate findings (CIFs) during surveillance, with 503 CIFs recorded. Of those patients with an "indeterminate" disease status at a point during surveillance, 79 were associated with contemporaneous TTMV-HPV DNA testing. TTMV-HPV DNA testing demonstrated high accuracy (97.5%; 77/79) in correctly determining recurrence status. Patients whose disease status was "indeterminate" at the time of a positive TTMV-HPV DNA test were clinically confirmed to recur faster than those whose disease status was "no evidence of disease." Only 3% of patients (17/543) experienced indeterminate TTMV-HPV DNA tests during surveillance. Discordance between TTMV-HPV DNA tests and clinical results was minimal, with only 0.6% (3/543) of patients showing positive tests without recurrence. Our findings support the utility of circulating TTMV-HPV DNA in resolving indeterminate disease status and informing the subsequent clinical course.

Identifiants

pubmed: 38878355
pii: S1368-8375(24)00192-1
doi: 10.1016/j.oraloncology.2024.106874
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106874

Informations de copyright

Copyright © 2024 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Scott A Roof (SA)

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: scott.roof@mountsinai.org.

James Jabalee (J)

Naveris, Inc., Waltham, MA, USA.

Eleni M Rettig (EM)

Center for Head & Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Susmita Chennareddy (S)

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Rocco M Ferrandino (RM)

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Sida Chen (S)

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Marshall R Posner (MR)

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Eric M Genden (EM)

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Raymond L Chai (RL)

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

John Sims (J)

CARTI Cancer Center, Little Rock, AR, USA.

Elaine Thrash (E)

CARTI Cancer Center, Little Rock, AR, USA.

Scott J Stern (SJ)

CARTI Cancer Center, Little Rock, AR, USA.

Noah S Kalman (NS)

Miami Cancer Institute, Miami, FL, USA.

Sreenija Yarlagadda (S)

Miami Cancer Institute, Miami, FL, USA.

Adam Raben (A)

Christiana Care, Helen F. Graham Cancer Center and Research Institute, Newark, DE, USA.

Lydia Clements (L)

The U.S. Oncology Network, Inc., Woodlands, TX, USA.

Abie Mendelsohn (A)

David Geffen School of Medicine at University of California, Los Angeles, CA, USA.

John M Kaczmar (JM)

Medical College of South Carolina Health-University Medical Center, Charleston, SC, USA.

Yadav Pandey (Y)

Medical College of South Carolina Health-University Medical Center, Charleston, SC, USA.

Mihir Bhayani (M)

Rush University Medical Center, Chicago, IL, USA.

Catherine Del Vecchio Fitz (C)

Naveris, Inc., Waltham, MA, USA.

Glenn J Hanna (GJ)

Center for Head & Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Classifications MeSH